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Abstract: Staphylococcus aureus, a versatile human pathogen, is commonly associated with medical device infections.  
Its capacity to establish and maintain these infections is thought to be related to its ability to form adherent biofilms. In 
this study, commercially available -amylase compounds from various biological sources were evaluated for their ability 
to reduce and prevent biofilm formation of several S. aureus isolates. Our data demonstrates that -amylase compounds 
can rapidly detach biofilms of S. aureus, as well as inhibit biofilm formation. Our data also demonstrates that -amylase 
compounds have an ability to reduce and disassociate S. aureus cell-aggregates grown in liquid suspension. These   
findings suggest that commercially available -amylase compounds could be used in the future to control S. aureus 
biofilm-related infections.  
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INTRODUCTION 
 Staphylococcus  aureus  is an important human pathogen, 
particularly in hospital settings, where it is a major source of 
life threatening bloodstream infections as well as a leading 
cause of implants and indwelling medical device infections 
[1-3]. S. aureus is well adapted to the human host and has a 
large number of factors that enable it to adhere to specific 
host substrates, evade host defenses, and resist antibiotic 
therapy [4-7]. One way in which the bacteria become resis-
tant to antibiotics and host defenses is believed to be through 
biofilm formation [8, 9]. 
  Biofilms are defined as communities of microorganisms 
that are encased in a self-synthesized extracellular polymeric 
matrix (EPS) and grow attached to a biotic or abiotic surface 
[10, 11]. Bacterial biofilms have a significant impact on hu-
man health [12, 13], as they frequently exhibit an enhanced 
pathogenic capability relative to bacteria in solution by vir-
tue of sessile behavior, increased resistance to antimicrobial 
agents, and the potential for detachment and distal emboliza-
tion of large biofilm fragments [14].  
  The increase in biofilm-related infection and the neces-
sity of both preventing and removing microbial biofilms 
from an infected site has led researchers to examine new 
ways to control surface attached bacteria. Among the tech-
niques proposed to control biofilms is the use of materials 
and
 coatings aimed at inhibiting initial cell adhesion, as well 
as a variety
  of treatments designed to reduce pre-existing
 
biofilms, such as heat, cleaning regimens, low-power laser,
 
sonication, chemical treatments, antibiotics, quorum sensing 
analogs, lectins, and biological control
 agents such as inver-
tebrates,
  protozoa, bacteriophages, and predatory bacteria
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[15-25]. Another biofilm control strategy makes use of en-
zymes that degrade major structural components of the EPS, 
resulting in removal of the biofilm. Among the EPS degrad-
ing enzymes that showed potential as anti S. aureus biofilm 
agents are deoxyribonuclease I (DNase I) and dispersin B 
(DspB) [26-30]. DNase I was shown to degrade extracellular 
DNA, which functions as a matrix adhesion molecule in 
biofilms produced by most bacterial species [31], whereas 
DspB degrades poly--1,6-N-acetyl-D-glucosamine (PNAG), 
an extracellular polysaccharide that also functions in biofilm 
matrix adhesion in numerous phylogenetically diverse gram-
negative and gram-positive bacteria [32-34].  
  In this study, we examined the potential use of commer-
cially available -amylase compounds as a method for   
inhibiting both cell-to-cell and cell-to-surface association of 
S. aureus, as well as the aptitude of the enzyme to detach 
pre-existing aggregates and biofilms of S. aureus.  
MATERIALS AND METHODS 
Bacterial Strains and Culture Conditions 
 The  following  S. aureus strains were used in this study: 
SH1000 (provided by Jeffrey Kaplan, Department of Oral 
Biology, UMDNJ) [28], SMC3256, a methicillin-resistant 
conjunctivitis clinical isolate, MU50, a vancomycin interme-
diate resistance conjunctivitis clinical isolate (both provided 
by Robert Shanks, Department of Ophthalmology, UPMC) 
[35], and 6 methicillin-sensitive S. aureus endophalmitis 
isolates, E253, E417, E424, E425, E427, and E442 (kindly 
provided by the Campbell Laboratory of Ophthalmic Micro-
biology, Department of Ophthalmology, UPMC). Staphylo-
coccus epidermidis NJ9709 was also used in the study [26]. 
Enzymes 
  The enzymes used in this study were: -amylase from 
Aspergillus oryzae (Sigma-Aldrich, St. Louis, MO, Catalog 22    The Open Microbiology Journal, 2011, Volume 5  Craigen et al. 
#10065),  -amylase from Bacillus subtilis (Sigma, catalog 
#10070),  -amylase from human saliva (Sigma, catalog 
#A1031), and -amylase from sweet potato (Sigma, catalog 
#A7005).  
Biofilm Formation Assay 
  Biofilm assay was performed similar to the previously 
described methods [36]. Overnight cultures of staphylococci 
were grown in liquid broth. Cultures were diluted, to an A600 
of 0.01 (1x10
8 CFU/ml), in tryptic soy broth (TSB) sup-
plemented with 0.6% yeast extract, 0.8% glucose, and 0.2% 
sodium citrate, to give TSB citrate media (TSBC). This me-
dium composition was selected for its ability to stimulate 
biofilm formation in S. aureus [35, 37]. One hundred micro-
liters of cells were added to individual wells of tissue cul-
ture-treated, 96-well polystyrene microtiter dishes (Costar, 
Corning Inc., Corning, NY). These were incubated in a 
closed, humidified plastic container for 18 hrs at 37
oC before 
being assayed for biofilm formation. Non-adherent cells 
were removed by washing and adherent cells were stained 
with 0.1% crystal violet (CV) as previously described [38]. 
S. epidermidis biofilms were developed in TSB media [26]. 
Photographs of the plate were taken with a Canon-scan 
4400F digital scanner, then the crystal violet was solubilized 
using 50% acetic acid for 10 min. Relative biofilm formation 
was assayed by measuring the absorbance of the crystal vio-
let solution at 600 nm (OD600). In addition to CV, biofilms 
were also stained and visualized by using 1 mg/ml Congo-
red (Sigma-Aldrich, St. Louis, MO), and 1 l/ml Pico-green 
dsDNA stain (Invitrogen, Eugene, OR). For biofilm forma-
tion on polyurethane, a polymer routinely used in the manu-
facture of medical devices, a polyurethane tube (Nalgene, 
Rochester, NY) was cut into 3mm pieces and inserted into a 
24-well costar plate. The well was filled with 0.5 ml of 
TSBC media containing S. aureus SH1000 cells and incu-
bated for 18 hrs to allow biofilm development. For statistical 
analyses, P values were determined by using a Student t-test 
performed with Microsoft Excel software. Error bars are 
shown as one standard deviation. 
Cell Aggregation Assay 
  Overnight cultures of staphylococci were diluted 1:1000 
in TSBC. Five ml of the cell suspension was placed in an 18 
mm glass tube and incubated for 18 hr at 37
oC on a TC-7 
tissue culture roller drum (New Brunswick Sci, New-
Brunswick, NJ) set on 30 RPM. To examine the aggregates, 
the cultures were poured into a 90 mm Petri-dish and visu-
ally examined. Fluorescent microscopy was used after 1 μl 
of Calcofluor-white (Sigma-Aldrich, St. Louis, MO) was 
added to the tube. To measure the extent of aggregation, the 
overnight culture tubes containing the aggregates were left to 
stand for 20 min to allow aggregates to settle to the bottom 
of the tube. Turbidity of the suspension (optical density of 
the suspension [ODs]) was measured at 600 nm. The culture 
was then dispersed by a 10s sonication step, using a VC505 
sonicator (Sonics and Materials Inc., Newtown, CT) and the 
total turbidity was measured (ODt). The percentage of ag-
gregation was estimated as follows: % aggregation = [(ODt – 
ODs) x 100]/ODt [21, 39]. As for the biofilm assay, TSBC 
medium was chosen for its ability to stimulate S. aureus cell 
clustering and aggregation [35, 37]. 
Inhibition and Reduction Assays 
  To assess the ability of the enzyme to inhibit biofilm 
formation or the formation of cell clusters (aggregates), 
biofilm or aggregation tubes were incubated for 18 hrs with 
or without (control) the enzyme before being analyzed. To 
measure the ability of the enzyme to reduce an existing 
biofilm, cells were first grown in 96-well plates for 18 hrs 
(pre-formed biofilm). Thereafter, non-adherent cells were 
removed and fresh TSBC medium, containing the enzyme, 
was added to the biofilm and incubated at 37
oC for the   
duration of the experiment. To evaluate the ability of the 
enzyme to disassociate S. aureus aggregates, enzyme was 
added directly to the tube containing overnight aggregates 
(pre-formed aggregates). The tubes were returned to incubate 
on the roller drum following aggregation quantification.  
Scanning Electron Microscopy 
  Experiments were performed as described previously [20, 
21]. In brief, S. aureus biofilms were developed on a 12x22 
mm PVC plastic cover slip. The cover slips were placed in a 
24-well polystyrene cell culture plate and incubated for 18 
hrs. Biofilms and enzymatic assays
  were prepared as de-
scribed above. S. aureus biofilms were rinsed to remove any 
planktonic cells before being fixed in 2% glutaraldehyde, 0.1 
M sodium cacodylate, and 0.1% ruthenium red. Images were 
viewed at the air-liquid interface using a Hitachi S-2500 
scanning electron microscope (SEM).  
RESULTS 
Biofilm Reduction and Inhibition Experiments 
  To assess the ability of -amylase to reduce an existing S. 
aureus biofilm, S. aureus SH1000 biofilms were developed 
in 96-well plates. Thereafter, the biofilms were washed and 
fresh TSBC media containing 100 mg/ml of -amylase com-
pound from A. oryzae was added to the wells. The plate was 
incubated for 10 min at 37
oC before being analyzed. As seen 
in Fig. (1A), a clear decrease in CV staining was observed in 
the amylase treated wells (Biofilm-reduction) compared to 
the initial biofilm (Pre-formed biofilm). The change in 
biofilm biomass was further assessed using CV quantifica-
tion. A significant 90% (P<0.001) reduction in CV staining 
was measured following a 10 min incubation period with the 
enzyme (1B, amylase) with a 5% drop in the control sample 
containing TSBC alone (1B, control). To further validate that 
the decrease in biofilm biomass is due to the enzyme activ-
ity, the enzyme was heat-deactivated (85
oC for 120 min). As 
seen in Fig. (1A and 1B), no reduction in CV staining   
was observed in the biofilms after incubation with the   
heat-deactivated enzyme. To assess the effect of the enzyme  
on a polysaccharide-based component that might be present  
in the biofilm, parallel wells were stained with Congo-red. A  
noticeable drop in biofilm Congo-red staining was seen fol-
lowing a 10 min enzyme treatment, compared to the robust 
staining in the initial biofilm (1A, Pre-formed) and in   
the control treated sample (data not shown). By using DNA 
stain and SEM imaging, we were able to further visualize 
changes in biofilm cell-surface coverage. A clear decrease  
in biofilm cell density was seen in the enzyme treated   
samples when compared to the initial biofilm, with the latter Controlling S. aureus Biofilms  The Open Microbiology Journal, 2011, Volume 5    23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Biofilm reduction and inhibition assay. (A) S. aureus SH1000 biofilms were developed for 18 hrs with (biofilm inhibition) or 
without (pre-formed biofilm) the addition of 100 mg/ml -amylase. In another experiment, S. aureus biofilms (pre-formed biofilm) were 
rinsed and exposed for 10 min to the enzyme (biofilm reduction) or to a heat-deactivated enzyme. Biofilms were rinsed and stained with CV, 
Congo-red or Pico-green (DNA stain). The experiments were also carried out on S. aureus biofilms developed on polyurethane tubes. For 
SEM imaging, biofilms were developed on PVC plastic cover slips. DNA stain was visualized under fluorescent microscope at 400X magni-
fication. Scanning electron micrographs were viewed at 500X magnification. Each experiment was carried out at least six times yielding simi-
lar results. (B) Quantification of biofilm reduction. Pre-formed overnight biofilms (Pre-formed) were incubated for 10 min with fresh TSBC 
media (Control), TSBC supplemented with 100 mg/ml enzyme (amylase), or heat deactivated enzyme (HD amylase). The wells were rinsed, 
stained with CV, and the amount of CV staining was quantified at A600 (OD 600). (C) Quantification of biofilm inhibition. S. aureus cells 
were cultured in 96-well plates with TSBC media (Control), media supplemented with 100 mg/ml enzyme (amylase), or heat deactivated 
enzyme (HD amylase). After 18 hrs the plates were rinsed, stained with CV, and the amount of CV staining was quantified. (D) Quantifica-
tion of S. epidermidis biofilm inhibition. S. epidermidis cells were cultured in 96-well plates with TSB media (Control) and media supple-
mented with 100 mg/ml enzyme (amylase). After 18 hrs, the plates were rinsed, stained with CV, and the amount of CV staining was quanti-
fied. (E) Quantification of S. epidermidis biofilm reduction. Pre-formed overnight biofilms (Pre-formed) were incubated for 4 hrs with fresh 
TSB media (Control) or TSB supplemented with 100 mg/ml enzyme (amylase). The wells were rinsed, stained with CV, and the amount of 
CV staining was quantified at A600 (OD 600). Each value represents the mean of 24 wells from one representative experiment. Error bars are 
shown as one-standard deviation. Each experiment was carried out three times yielding similar results. 24    The Open Microbiology Journal, 2011, Volume 5  Craigen et al. 
 
exhibiting a substantial biofilm cell population attached to 
the surface (Fig. 1A).  
  In another experiment, the ability of the enzyme com-
pound to inhibit biofilm formation was evaluated. S. aureus 
SH1000 cells were incubated in TSBC media (control) or 
TSBC media supplemented with 100 mg/ml of -amylase 
from A. oryzae. The biofilms were left to develop at 37
oC for 
18 hrs before the extent of biofilm formation was measured. 
As before, a robust biofilm developed in the wells incubated 
with TSBC (1A, Pre-formed). However, a significantly 
(P<0.001) reduced biofilm formed in the wells which were 
incubated simultaneously with the enzyme during biofilm 
development, as seen by CV, Congo-red, DNA, and SEM 
imaging (1A, biofilm inhibition). CV quantification revealed 
that biofilm development in the presence of the enzyme was 
80% less than the biofilm buildup in either TSBC media 
alone or TSBC media supplemented by heat-deactivated 
enzyme (1C, amylase, Control, and HD amylase, respec-
tively). The ability of the enzyme to both reduce and inhibit 
biofilm formation was consistent on all of the examined sur-
faces, which included polystyrene (used in the 96-well 
plates), PVC (used for SEM imaging), and polyurethane 
(Fig. 1A, polyurethane tubes). Although the -amylase com-
pound was shown to both inhibit and reduce biofilm buildup 
of S. aureus, it was not efficient in controlling S. epidermidis 
biofilms.  Similar biofilm accumulation was measured in 
wells inoculated with S. epidermidis alone  and  S. epider-
midis  supplemented with  100 mg/ml -amylase (Fig. 1D).  
-amylase also did not cause S. epidermidis biofilm   
detachment with biofilm measuring A600=2.8 in wells   
that were incubated for 4 hrs with -amylase or TSB control 
(Fig. 1E). 
  In order to investigate whether the biofilm reducing and 
inhibiting effect could be attributed to loss of cell viability, 
5x10
8 CFU/ml S. aureus SH1000 were incubated overnight 
in PBS buffer containing 100 mg/ml A. oryzae  -amylase 
compound. No reduction in cell viability was measured after 
a 24 hr incubation period, with 4x10
8 CFU/ml remaining in 
the samples maintained in PBS alone or PBS with amylase. 
The enzyme also did not exhibit any bactericidal or bacte-
riostatic effect when incubated for 24 hrs with S. aureus, 
reaching a cell density of 6.2x10
9,
  6.1x10
9, and
  5.8x10
9 
CFU/ml when incubated in the presence of TSBC, TSBC 
supplemented with 100 mg/ml amylase, and TSBC contain-
ing 200 mg/ml amylase, respectively.  
  A time point experiment in which S. aureus SH1000 pre-
formed biofilms were incubated in the presence of 100 
mg/ml enzyme demonstrated that the biofilm reducing activ-
ity is extremely rapid, reducing 79% of the existing biofilm 
within 5 min, and reaching 89% reduction after 30 min of 
incubation. No significant increase in biofilm reduction was 
measured following an additional 24 hr incubation period 
(Fig.  2A). In order to examine the minimal concentration 
required to effectively remove the biofilm, serial diluted en-
zyme was added to the pre-formed biofilm. A 90%, 89%, 
and 72% reduction was observed in the wells which were 
incubated for 45 min with 100, 20, and 10 mg/ml enzyme, 
respectively, with a 36% and 23% reduction measured in the 
wells incubated with 2 and 1 mg/ml (Fig. 2B, white bars). By 
24 hrs, a reduction greater than 77% was seen in all of the 
examined enzyme concentrations (Fig. 2B, gray bars). Incu-
bating S. aureus cells in the presence of 100 to 1 mg/ml en-
zyme also demonstrated a positive correlation between the 
enzyme quantity present in the well and biofilm inhibition, 
with 82% 81%, 80%, 68%, and 64% less biofilm buildup in 
the wells incubated with 100, 20, 10, 2, and 1 mg/ml en-
zyme, respectively, as compared to the biofilm in enzyme- 
free media (Fig. 2C, Control).  
The Effect of -amylase on S. Aureus Clinical Isolates 
  To examine the effect of -amylase compound on differ-
ent S. aureus isolates, 8 additional S. aureus clinical isolates 
were grown in TSBC media with and without the enzyme. 
As seen in Fig. (3A), the biofilms produced in the presence 
of the enzyme (3A, biofilm inhibition) were less robust than 
those grown in enzyme-free media (3A, pre-formed biofilm). 
These results were also confirmed by CV quantification that 
demonstrated a decrease of 65% to 83% in biofilm formation 
(3B, gray bars), with the exception of S. aureus 427, which 
had 38% less biomass in the treated sample.  Treating the 
pre-formed biofilms with the enzyme for 10 min brought 
about a measurable decrease in all of the isolates examined, 
with the most significant decreases of 70%-80% measured 
for S. aureus isolates 442, 417, 425, and 253, and more mod-
est reductions of 45%-60% measured for isolates 424, 427, 
MU 50 and SMC 3256 (Fig. 3C). 
Biofilm Inhibition and Reduction by amylases from   
Different Biological Sources 
  To compare the biofilm reducing ability of commercially 
available amylase compounds isolated from different bio-
logical sources, S. aureus SH1000 was incubated with 10 
mg/ml of the following enzymes: -amylase compound from 
B. subtilis,  -amylase compound from human saliva, -
amylase compound from sweet potato, and -amylase com-
pound from A. oryzae, which was used as a positive control 
in this experiment. After 10 min of incubation, a substantial 
reduction in biofilm CV staining was seen only in the wells 
incubated with -amylase from A. oryzae (Fig. 4A and 4B, 
white bars).  However, by 3 hrs, a significant reduction 
(P<0.001) was also observed in the wells incubated with -
amylase from B. subtilis (4B, gray bars). No substantial 
biofilm reduction was measured for the pre-formed biofilms 
incubated with -amylase compound and -amylase com-
pound from human saliva. In contrast to their biofilm reduc-
ing aptitude, all of the -amylase compounds exhibited some 
biofilm inhibiting capability when incubated in the presence 
of S. aureus cells (Fig. 4C), with the most potent inhibiting 
effect measured for -amylase compound from A. oryzae 
(77% inhibition), B. subtilis (88% inhibition),  and human 
saliva (89% inhibition). A more moderate, but measurable, 
inhibition registered in wells containing -amylase from 
sweet potato (49% inhibition).  
  Since the purity of the commercially acquired com-
pounds is not fully known, biofilm inhibition experiments 
were conducted in which S. aureus SH1000 was incubated in 
the presence of -amylase from A. oryzae with and without 
the addition of a protease inhibitor (Halt
tm protease inhibitor 
cocktail, Thermo Scientific, Rockford, IL). The addition of 
protease inhibitor did not reduce the biofilm inhibiting effect 
of the amylase compound, with biofilm buildup reaching 
A600=0.52, 0.56 and 3.17 in wells inoculated with amylase Controlling S. aureus Biofilms  The Open Microbiology Journal, 2011, Volume 5    25 
alone, amylase plus protease inhibitor and amylase free con-
trol, respectively. Protease inhibitor cocktail also did not 
abolish the ability of the amylase compound to remove a 
preformed biofilm with a 70±1.8% reduction in wells inocu-
lated with amylase alone and 66±4% reduction in wells con-
taining amylase plus protease inhibitor. To determine 
whether DNase is present in the amylase compound, -
amylase from A. oryzae was prepared and spotted on Difco
Tm 
DNase test agar plates with methyl green (BD, Franklin 
Lakes, NJ). No DNase activity was seen after incubating the 
plates for up to 48 hrs (data not shown).  
Aggregation Reduction and Inhibition Experiments 
  In the previous experiments, emphasis was put on the 
ability of the enzyme to detach pre-formed biofilms or in-
hibit the attachment of cells to the examined surface, leading 
to biofilm reduction and inhibition. In the following experi-
ments, the aim was to investigate whether cell-to-cell asso-
ciations could also be affected by the presence of -amylase 
compound in the surrounding media. To this end, a bioassay 
was performed in which cells were grown in TSBC media in 
order to stimulate cell-to-cell association and aggregation. 
The ability of the enzyme to inhibit the formation of the ag-
gregate was achieved by simultaneously incubating the cells 
with 50 mg/ml of the enzyme from A. oryzae during growth. 
As seen in (Fig. 5A) growing S. aureus SH1000 cells in 
TSBC resulted in the formation of extremely large macro-
colonies (>1mm) that were visible by eye (Fig. 5A, Pre-
formed aggregates). These macro-colonies, composed of 
hundreds of cells, were positively stained by the polysaccha-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Enzyme efficacy. (A) Quantification of biofilm reduction at different time points. S. aureus SH1000 biofilms were developed in 96 
well plates for 18 hrs (Pre-formed). Thereafter, the wells were rinsed and incubated with fresh TSBC media (white bars) or 100 mg/ml en-
zyme (gray bars). The wells were than rinsed, stained with CV, and the amount of CV staining was quantified. (B) Quantification of biofilm 
reduction at different enzyme concentrations. S. aureus biofilms were developed in 96 well plates for 18 hrs (Pre-formed). Thereafter, the 
wells were rinsed and incubated with fresh TSBC media (Control) or media supplemented with 100 to 1 mg/ml enzyme. CV staining and 
quantification was assessed after 45 min (white bars) and 24 hrs (gray bars) of incubation. (C) Quantification of biofilm inhibition at differ-
ent enzyme concentrations. S. aureus cells were cultured in 96-well plates with media (Control) or TSBC supplemented with 100 to 1 mg/ml 
enzyme. The extent of biofilm formation was analyzed after 18 hrs. Each value represents the mean of 16 wells from one representative ex-
periment. Error bars are shown as one-standard deviation. 26    The Open Microbiology Journal, 2011, Volume 5  Craigen et al. 
ride stain Calcofluor-white and visualized by light and fluo-
rescence microscopy (Fig. 5A). Large macro-colonies did 
not develop in tubes that contained the enzyme (5A, Aggre-
gate inhibition). Light microscopy also confirmed the ab-
sence of macro-colonies in the enzyme- treated sample, as 
only relatively small cell clusters, consisting of 2-10 cells, 
were formed. In order to quantify the extent of macro-colony 
inhibition, S. aureus isolates SH1000, 427, 442, and SMC 
3256 were grown in the presence of the enzyme and the ex-
tent of aggregation was analyzed. These isolates were se-
lected for their enhanced aggregation phenotype in TSBC 
media. After 18 hrs of incubation, 53% to 76% of the cells 
were present in aggregates (Fig. 5B, white bars). In contrast, 
only 6%-12% aggregation was measured in the enzyme- 
treated tubes (Fig. 5B, gray bars).  
  In another experiment, the ability of the enzyme to de-
grade existing macro-colonies was evaluated by adding 100 
mg/ml  -amylase compound from A. oryzae into the pre-
formed aggregate tube. Within 3 hrs of incubation, a clear 
reduction in macro-colonies was seen, with aggregates of 
only 20 cells or less remaining in the enzyme- treated sample 
(Fig.  5A, aggregate reduction). Quantifying the extent of 
reduction revealed decreases of 59%, 66%, 74%, and 79% in 
SH1000 aggregation within 30 min, 1hr, 2hr and 3hr incuba-
tion periods, respectively. Aggregation reductions of 77%, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Enzymatic effect on S. aureus clinical isolates. (A) S. aureus clinical isolates were cultured in 96-well plates with TSBC media 
(Pre-formed biofilm) or TSBC supplemented with 100 mg/ml enzyme (biofilm inhibition). In a parallel experiment, the pre-formed biofilms 
were incubated for 10 min with the enzyme (biofilm reduction) before being rinsed and stained. Quantification of biofilm inhibition (B) and 
reduction (C), following exposure to TSBC media alone (white bars) or TSBC containing enzyme (gray bars). Each value represents the 
mean of 8 wells from one representative experiment. Error bars are shown as one-standard deviation. Controlling S. aureus Biofilms  The Open Microbiology Journal, 2011, Volume 5    27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Enzymatic effect of amylases from different biological sources on S. aureus biofilms. (A) S. aureus SH1000 was cultured for 24 
hrs in 96-well plates with TSBC media (pre-formed biofilm) or TSBC supplemented with 10 mg/ml of -amylase (biofilm inhibition) from A. 
oryzae, B. subtilis, and human saliva and -amylase from sweet potato. In a parallel experiment, the pre-formed biofilms were incubated for 3 
hrs (biofilm reduction) before being rinsed and stained. (B) Quantification of biofilm reduction. Pre-formed biofilms were exposed to the 
enzymes for 10 min (white bars), 3 hrs (gray bars), and 24 hrs (black bars) before being stained with CV. (C) Quantification of biofilm inhibi-
tion. S. aureus was cultured for 24 hrs in 96-well plates with TSBC media (Control) or TSBC supplemented with 10 mg/ml of each   
enzyme. Each value represents the mean of 6 wells from one representative experiment. Error bars are shown as one-standard deviation. 28    The Open Microbiology Journal, 2011, Volume 5  Craigen et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Aggregation reduction and inhibition experiments. (A) S. aureus SH1000 cells were grown in 18 cm glass tubes containing 
TSBC media (Pre-formed aggregates) or TSBC supplemented with 100 mg/ml enzyme (Aggregate inhibition) and incubated on a tissue cul-
ture roller at 30 RPM. After 18 hrs, the tubes were poured into a 90 mm Petri-dish and visualized by eye and by light microscopy at 400X 
magnification. Aggregates were also stained for 10 min with 1 μl of Calcofluor-white before being viewed by fluorescent microscopy, magni-
fication set at 400X. To measure the ability of the enzyme to disassociate the aggregates, pre-formed SH1000 aggregates were incubated for 3 
hrs with 50 mg/ml enzyme (Aggregate reduction). Quantification of aggregation inhibition (B) and reduction (C) of four S. aureus isolates 
following exposure to TSBC media alone (white bars) or TSBC containing enzyme (gray bars). Each experiment was carried out four times, 
yielding similar results. Value represents data from one representative experiment. 
70%, and 65% were measured for isolates 427, 442, and 
SMC 3256 following a 3 hr incubation period (Fig. 5C).  
DISCUSSION 
  In the last few years, biofilm formation has become an 
increasing source of concern in industrial, environmental and 
medical settings. This is especially true in orthopedic medi-
cine, where biofilms pose a significant challenge and can 
result in some of the most serious complications involving 
prosthetic and other medical device infections, impacting 
morbidity, mortality, and medical costs [40]. The necessity 
of removing the biofilm from the infected site usually re-
quires surgical intervention and radical antimicrobial therapy 
[41]. A possible therapeutic approach to medical device in-
fections involves the use of EPS-degrading agents that might 
block, inhibit or reduce cell-to-cell and cell-to-surface asso-
ciations within the biofilm, bringing about the release of 
planktonic cells into the environment and allowing the host 
immune system and antimicrobial drugs to eliminate the in-
fection [42, 43].  Controlling S. aureus Biofilms  The Open Microbiology Journal, 2011, Volume 5    29 
  In this study, we examined the potential use of commer-
cially available -amylase compounds as a biofilm control 
agent against S. aureus. Our work demonstrated that, when 
grown in the presence of the enzyme, a significant reduction 
in biofilm buildup is achieved. The biofilm inhibition effect 
was observed with all of the examined S. aureus isolates and 
was not influenced by the chemical composition of the sur-
face on which the biofilm developed. A measurable reduc-
tion in biofilm buildup was also seen for S. aureus biofilms 
incubated with -amylase compounds derived from bacterial, 
fungal, and human origin. However, a reduced inhibiting 
effect was registered for -amylase. The difference in 
biofilm reduction could be attributed to the fact that -
amylase is an exo-acting carbohydrolase which hydrolyzes 
the  -1,4-glucosidic linkages of starch only from the non-
reducing end of the polysaccharide, as opposed to -amylase, 
which can act simultaneously anywhere on the substrate, 
thus -amylase tends to be faster-acting than -amylase [44]. 
In addition to the enzyme’s capacity to inhibit the formation 
of S. aureus biofilms, -amylase also rapidly reduced exist-
ing pre-formed biofilms at concentrations as low as 10 
mg/ml, with a 1-mg/ml enzyme concentration requiring 
longer incubation periods to achieve comparable biofilm 
reduction. As was demonstrated for biofilm inhibition, the 
biofilm reducing ability was consistent on all of the surfaces 
and isolates tested as well as with -amylase compounds 
derived from A. oryzae and B. subtilis. However, it is   
interesting to note that -amylase from human saliva only 
produced a limited drop in biofilm biomass and that   
no reduction was observed in the biofilms incubated with   
-amylase.  
  Biofilms in most settings are multicellular structures 
composed of both cell-to-surface and cell-to-cell associa-
tions. In order to examine the effect of the -amylase com-
pound specifically on cell-to-cell interactions, experiments 
were conducted in conditions that stimulated cell clustering 
and aggregation. Here too, -amylase from A. oryzae had the 
potency to inhibit the formation of S. aureus aggregates as 
well as reduce pre-existing aggregates.  
  It was previously suggested that EPS degrading enzymes 
have a biological role in enabling surface attached cells to 
dislodge from one site and relocate, for example, Aggregati-
bacter actinomycetemcomitans biofilm detachment and dis-
persal is mediated by the production of dispersin B, a poly--
1,6-N-acetyl-D-glucosamine (PNAG) hydrolyzing enzyme 
[45-47]. The biological role of dispersin B in A. actinomy-
cetemcomitans and the fact that PNGA is produced in other 
bacteria such as S. aureus, S. epidermidis, Escherichia coli, 
Actinobacillus pleuropneumoniae, Yersinia pestis, and Bor-
detella spp. led to studies aimed at using the enzyme to de-
tach biofilms as well as a means of enhancing the effective-
ness of antimicrobial agents [27-29, 47-50]. In addition to 
dispersin B, other carbohydrate degrading enzymes were 
shown to have an effect on biofilm EPS components. In 
Pseudomonas aeruginosa, degradation of the alginate by 
alginate-lyase enhanced antibiotic biofilm killing [51], 
whereas the use of cellulase was shown to degrade a carbo-
hydrate-rich component of
  the matrix. This cellulase-
sensitive sugar was also shown to bind Congo-red and is 
essential for P. aeruginosa pellicle formation and biofilm 
structure [52, 53]. The role of an amylose-like polysaccha-
ride in biofilm formation was also documented in Salmonella 
enteritidis [54], Agrobacterium tumefaciens [55], Pseudo-
monas spp. CE-2 [56], P. putida [57] and Streptomyces 
coelicolor, in which cellulose-anchored amyloidal fimbriae 
were shown to mediate biofilm formation [58]. The success-
ful use of proteolytic enzymes with other polysaccharide 
degrading enzymes, including -amylase, as means to re-
move biofilms, was recently demonstrated for bacteria found 
in the food and brewing industry, including Bacillus cereus, 
P. fluorescens,  Flavimonas oryzihabitans, Lactobacillus   
brevis, Leuconostoc mesenteroides and  Saccharomyces  
cerevisiae [59-61]. 
  The use of enzymes capable of specifically degrading the 
constituents of the extracellular S. aureus matrix was the 
focus of other studies. Chaignon and his colleagues demon-
strated that treating S. aureus strain 383 biofilms with prote-
inase K and trypsin, as well as pancreatine and Pectinex Ul-
tra SP, leads to biofilm detachment, however, biofilm reduc-
tion was not seen when dispersin B or sodium periodate was 
applied [50]. Since both Pectinex Ultra SP and Pancreatin 
are multi-component enzyme preparations containing prote-
ase activity and a wide range of carbohydrolases, it was dif-
ficult to attribute the biofilm reducing effect to any single 
enzyme [62]. The inability to reduce a pre-existing S. aureus 
biofilm by dispersin B was also concurred by Jeffrey Kap-
lan’s group. However, their study did demonstrate that dis-
persin B is effective in inhibiting biofilm formation of the 
SH1000 strain [28]. Thus, the discrepancy in the ability of an 
enzyme to reduce S. aureus biofilms at early vs. late stages 
of biofilm formation is consistent with our finding that some 
amylase compounds were more competent at inhibiting 
biofilm buildup than reducing existing biofilms. In addition 
to the proteolytic and PNAG-modifying enzymes, DNase-I 
was also shown to be effective in inhibiting and reducing S. 
aureus SH1000 biofilms [28].  
  In this study, we have used several commercially avail-
able -amylase compounds. As it is difficult to guarantee the 
purity of the compounds, we could only speculate that the 
biofilm controlling aptitude of the compounds resulted from 
the amylase activity. The finding that several -amylase 
compounds had an ability to control S. aureus biofilms, in 
concert with the fact that the enzyme activity was not inhib-
ited in the presence of protease inhibitors nor did it possess 
any DNase activity, lessen the possibility that the biofilm 
removal effect was caused by other enzymes, which might 
also be present in the acquired compounds. Furthermore, the 
inability of the compounds to affect S. epidermidis biofilms 
suggests that the activity of the enzyme is not through the 
degradation of the PNAG matrix, as this would have affected 
the stability of the PNAG rich S. epidermidis biofilms [28]. 
  At this point, we can only speculate on the exact origin of 
the substrate being degraded by the amylase compounds, as 
the composition of S. aureus biofilms are quite diverse and 
could vary depending on the strain, the biofilm growth con-
ditions, and the biofilm developmental stage [28, 35, 63-65]. 
However, based on the research conducted so far, we believe 
that commercially available polysaccharide-modifying com-
pounds could be used in the future as a preventative meas-
ure, to prevent the establishment of a biofilm, or as a method 
used to eradicate an already existing biofilm infection.  30    The Open Microbiology Journal, 2011, Volume 5  Craigen et al. 
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